Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Conditions: BRAF V600E Negative; KRAS Gene Mutation Negative; Locally Advanced Unresectable Colorectal Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; NRAS Gene Mutation Negative; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8 Interventions: Biological: Cetuximab; Drug: Irinotecan; Biological: Panitumumab; Drug: Regorafenib Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials